Lab Manager | Run Your Lab Like a Business

Webinars: Webinar: Clinical Impact of Enhanced Resolution of Vitamin D Metabolites through Chromatographic Selectivity

Webinar Details
Webinar: Clinical Impact of Enhanced Resolution of Vitamin D Metabolites through Chromatographic Selectivity
Posted on:

In this presentation, a review of the clinical importance of distinguishing the epimeric forms of vitamin D metabolites is discussed with emphasis on LC-MS/MS analysis.

Live Air Date: Tuesday, September 23, 2014

Increasing health concerns related to vitamin D deficiency including Alzheimer’s and immune diseases, along with various cancers, have heightened awareness of the nutrient. As the associated health concerns grow, so does the need for fast and accurate analytical testing for diagnostics and treatment. This has driven the interest in more specific LC–MS/MS methodology where specificity is gained through chromatographic and MS resolution. There is a growing interest in the presence of the C3-epimeric form of 25(OH) D (3-epi-25-hydroxyvitamin D [3-epi-25(OH) D]3) in human serum, especially in infants. Although it is still unclear what role the epimeric form plays, or the degree of interference it causes, it is presently regarded as important to remove the C3 epimer from measured 25(OH)D3 in order to report diagnostic results in affected patients. In this presentation, a review of the clinical importance of distinguishing the epimeric forms of vitamin D metabolites is discussed with emphasis on LC-MS/MS analysis.

The role of chromatographic selectivity in LC-MS/MS analysis is also discussed for both the LC separation along with the sample preparation step. The end result demonstrates how selectivity, both chromatographic and MS, enable LC-MS/MS clinical assays to allow more accurate and precise results over traditional immunoassays.

Speakers

Michael Wright is a senior scientist with 15 years of quantitative HPLC and Mass Spectrometry experience in the clinical diagnostic sector. He has been involved in the fields of new born screening, gastro-intestinal permeability, investigation of metabolic disease, endocrinology and therapeutic drug monitoring, amongst other clinical chemistry analysis. After a number of years working in the United Kingdom, at London’s at Guys & St Thomas’ and King’s College hospitals, followed by Cambridge University Hospital Trust, he has relocated back to his home country of Australia where he has been appointed the section leader for the Clinical Chemistry and Endocrinology LC-MS division at the Prince of Wales Hospital in Sydney.

Craig Aurand is a Principal Research Scientist at the Supelco division of Sigma-Aldrich; he provides applications development for both chromatographic separations and sample preparation. Craig’s primary role is in support of bioanalytical method development for small molecules, along with R&D product development for sample preparation with an emphasis in mass spectrometry. He is responsible for the development of sample preparation devices for bioanalytical applications, and has numerous presentations and publications focusing on novel chromatographic separations and sample preparation techniques. His most recent research is focused on micro-sampling techniques in the bioanalysis field.

Sponsor

Related Articles